One can make an argument for Ampakines as cognitive enhancers in mild AD--but then again, you can make an argument for nicotinics, 5HT-6, PDE4, mGluR approaches, and more in the same vein. Highly competitive--it'd be a perfectly reasonable secondary target for a low-impact, but that's not the real key to a huge AD drug. Altering disease course is where they have to head. And I have yet to see a good case made for low-impacts as neurotrophics.
NeuroInvestment
News 
Market Data 
Discover 
AI
